Comment on “Effectiveness of a Group B outer membrane vesicle meningococcal vaccine in preventing hospitalization from gonorrhea in New Zealand: a retrospective cohort study, Vaccines, 2019, 1, 5; doi:10.3390/vaccines7010005”
Available evidence suggests MeNZB™ is not associated with a durable effect against N. gonorrhoeae.
Main Author: | Chris Kenyon |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-03-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | http://www.mdpi.com/2076-393X/7/1/31 |
Similar Items
-
Exploitation of Neisseria meningitidis Group B OMV Vaccines Against N. gonorrhoeae to Inform the Development and Deployment of Effective Gonorrhea Vaccines
by: Helen Petousis-Harris, et al.
Published: (2019-04-01) -
Impact of meningococcal group B OMV vaccines, beyond their brief
by: Helen Petousis-Harris
Published: (2018-05-01) -
Evaluating the effectiveness of the 4CMenB vaccine against invasive meningococcal disease and gonorrhoea in an infant, child and adolescent program: protocol
by: Helen S. Marshall, et al.
Published: (2021-05-01) -
An Observational Study to Assess the Effectiveness of 4CMenB against Meningococcal Disease and Carriage and Gonorrhea in Adolescents in the Northern Territory, Australia—Study Protocol
by: Helen S. Marshall, et al.
Published: (2022-02-01) -
Reply to “Comment on Effectiveness of a Group B Outer Membrane Vesicle Meningococcal Vaccine in Preventing Hospitalization from Gonorrhea in New Zealand: A Retrospective Cohort Study, Vaccines, 2019, 1, 5; doi:10.3390/vaccines7010005”
by: Janine Paynter, et al.
Published: (2019-03-01)